ADGM

Business Context and Reporting Period

Company: Adagio Medical Holdings, Inc. (ADGM)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024. The report is split into two periods due to a Business Combination (SPAC merger) with ARYA Sciences Acquisition Corp IV on July 31, 2024: Predecessor (Jan 1 – July 30, 2024) and Successor (July 31 – Dec 31, 2024).
Business Overview: Adagio is a medical device company developing Ultra-Low Temperature Cryoablation (ULTC) technology to treat ventricular tachycardia (VT). The company holds CE Mark approval in Europe but is awaiting FDA approval in the U.S. following the completion of its FULCRUM-VT pivotal clinical trial, expected in late 2025.

Key Financial Metrics

Note: The Successor period includes significant non-cash impairment charges not present in prior periods.

Material Changes vs. Prior Period

• Impairment Charges: The Successor period recorded a $30.3 million goodwill impairment and an $18.9 million intangible asset impairment, driven by a sustained decline in share price and market capitalization. These charges were absent in 2023 and the Predecessor period.
• Revenue Growth: Revenue increased 101% year-over-year to $0.6 million for the full year 2024, primarily due to increased consumable sales in European markets.
• Expense Reduction: Research and Development (R&D) expenses decreased 21% year-over-year to $12.2 million (combined periods), attributed to the receipt of CE Marking in March 2024 reducing certain development costs.
• SG&A Increase: Selling, General, and Administrative expenses increased 74% year-over-year, largely due to $5.2 million in transaction costs related to the Business Combination.
• Capital Structure: The company transitioned from various bridge financing notes to a consolidated $20.0 million Convertible Securities Note structure following the merger.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Strategic Restructuring: In February 2025, the company announced a restructuring to prioritize the U.S. FULCRUM-VT pivotal trial and product design optimization. This includes pausing the limited European launch of the vCLAS catheter.
• Cash Burn: Management projects a cash burn of approximately $20.0 million for the 12 months following the issuance of the financial statements (April 2025 – March 2026).
• Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. Current cash balances ($20.6 million) are deemed insufficient to fund operations for the next 12 months without additional financing.
• Regulatory Milestone: The FULCRUM-VT trial is expected to complete in the second half of 2025, supporting a future FDA submission.

Key Risks and Contingencies

• Material Weaknesses: The company identified material weaknesses in internal controls over financial reporting related to the review of third-party valuation reports for debt and equity instruments.
• Nasdaq Compliance: The company is currently not in compliance with Nasdaq audit committee requirements due to a director resignation, with a cure period extending to January 2026.
• Financing Needs: The company must raise additional capital to fund operations and clinical trials. Failure to do so could force a reduction or cessation of R&D activities.
• Convertible Notes: The $20.0 million Convertible Securities Notes carry a 13% interest rate and include covenants that could trigger default or acceleration if not met.

Investor Verification Checklist

• Liquidity Runway: Verify the status of any new equity or debt financing secured after the filing date to address the "substantial doubt" regarding going concern status.
• Internal Control Remediation: Monitor progress on remediation plans for the identified material weaknesses in financial reporting controls.
• Nasdaq Compliance: Confirm the company's progress in regaining compliance with Nasdaq audit committee listing rules.
• Clinical Trial Progress: Track enrollment and data readout timelines for the FULCRUM-VT pivotal trial, which is critical for U.S. commercialization.
• Restructuring Impact: Assess the financial impact of the February 2025 restructuring, including the pause on European sales and workforce reductions.